SynDermix attends virtual BIO International Convention 2020 – BIO Digital
(more…)
SynDermix is a Swiss developer of innovative health technologies that focuses on the development of effective and safe treatments that meaningfully respect patient convenience and address important unmet medical needs.
SynDermix attends virtual BIO International Convention 2020 – BIO Digital
(more…)
Delegate of the Board and Chief Executive Officer of SynDermix AG, Mr. Dieter Hemmer, on medical leave of absence; Dr. Konstantinos Efthymiopoulos appointed Designated Managing Director until the AGM 2020
(more…)
SynDermix AG announced temporary postponement of initiation of the SDX-3101 clinical trial on chronic rhinosinusitis without nasal polyps due to the novel coronavirus pandemic. (more…)
SDX-31 is an electronic medical device platform based on Precisely Modulated Acoustic Energy™ (PMAE) therapy; a proprietary type of treatment during which digitally controlled acoustic frequencies are generated
SDX-21 is a platform based on an endogenous Nitric Oxide (NO) donor in an easy-to-use formulation, which can be leveraged for the development of drug products or medical devices, depending on the selected indication
Together, our executive team, specialist partners and company values combine to sustain ground-breaking health science and process excellence.
SynDermix is a privately funded company. Investors and other account holders, please click here to log in.